Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Novotny

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Gastroenterology|February 24, 2026
Impact of itopride on functional dyspepsia symptom progression: a multicenter noninterventional postregistration studyJiri Dolina, Jan Tack, Serhiy Forostyak, et al.
International Journal of Molecular Sciences|August 27, 2021
Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and NeurodegenerationPatrik Oleksak, Michal Novotny, Jiri Patocka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 11, 2023
The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's diseaseMartin Valis, Alzbeta Dlabkova, Jakub Hort, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 2023
Corrigendum to "The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease" [Biomed. Pharmacother. 159 (2023) 114223]Martin Valis, Alzbeta Dlabkova, Jakub Hort, et al.
European Neurology|July 20, 2023
Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple SclerosisMarek Peterka, Martin Valis, Ondrej Soucek, et al.
Frontiers in Public Health|January 23, 2024
Pregabalin use in forensic hospitals and prisons in German speaking countries-a survey study of physiciansMichal Novotny, Jan Bulla, Daniela Hubl, et al.
Multiple Sclerosis and Related Disorders|June 24, 2021
Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groupsZbysek Pavelek, Michal Novotny, Ondrej Soucek, et al.
Journal of Immunology Research|April 17, 2023
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON MonitorZbysek Pavelek, Ondrej Soucek, Jan Krejsek, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|December 6, 2022
Long-Term Averaged Spectrum Descriptors of Dysarthria in Patients With Parkinson's Disease Treated With Subthalamic Nucleus Deep Brain StimulationJan Svihlik, Michal Novotny, Tereza Tykalova, et al.
Multiple Sclerosis and Related Disorders|November 18, 2017
Characteristics of motor speech phenotypes in multiple sclerosisJan Rusz, Barbora Benova, Hana Ruzickova, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Gastroenterology|February 24, 2026
Impact of itopride on functional dyspepsia symptom progression: a multicenter noninterventional postregistration studyJiri Dolina, Jan Tack, Serhiy Forostyak, et al.
International Journal of Molecular Sciences|August 27, 2021
Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and NeurodegenerationPatrik Oleksak, Michal Novotny, Jiri Patocka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 11, 2023
The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's diseaseMartin Valis, Alzbeta Dlabkova, Jakub Hort, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 29, 2023
Corrigendum to "The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease" [Biomed. Pharmacother. 159 (2023) 114223]Martin Valis, Alzbeta Dlabkova, Jakub Hort, et al.
European Neurology|July 20, 2023
Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple SclerosisMarek Peterka, Martin Valis, Ondrej Soucek, et al.
Frontiers in Public Health|January 23, 2024
Pregabalin use in forensic hospitals and prisons in German speaking countries-a survey study of physiciansMichal Novotny, Jan Bulla, Daniela Hubl, et al.
Multiple Sclerosis and Related Disorders|June 24, 2021
Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groupsZbysek Pavelek, Michal Novotny, Ondrej Soucek, et al.
Journal of Immunology Research|April 17, 2023
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON MonitorZbysek Pavelek, Ondrej Soucek, Jan Krejsek, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|December 6, 2022
Long-Term Averaged Spectrum Descriptors of Dysarthria in Patients With Parkinson's Disease Treated With Subthalamic Nucleus Deep Brain StimulationJan Svihlik, Michal Novotny, Tereza Tykalova, et al.
Multiple Sclerosis and Related Disorders|November 18, 2017
Characteristics of motor speech phenotypes in multiple sclerosisJan Rusz, Barbora Benova, Hana Ruzickova, et al.
Pageof 5